Hybrid Ablation of Atrial Fibrillation in Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT05411614
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 120 participants
- Sponsor
- St. George's Hospital, London
- Registry
-
NCT05411614
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05411614. Randomized; single masking; primary purpose treatment. Start 2022-06-25 (actual); primary completion 2026-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Hybrid Ablation of Atrial Fibrillation in Heart Failure
- Acronym
- HALT AF
- Condition
- Persistent Atrial Fibrillation
- Condition
- Atrial Fibrillation, Persistent
- Condition
- Atrial Arrhythmia
- Condition
- Atrial Fibrillation
- Condition
- Heart Failure
- Condition
- Left Ventricular (LV) Systolic Dysfunction
- Intervention (Device)
- AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip
- Intervention (Device)
- Endocardial Catheter Ablation
- Lead sponsor
- St. George's Hospital, London
Record details
- Record id
cardio:ct-nct05411614- Content hash
e9ff1274083408093142ed18a44db8a965cc6a63832ff719562b26303d43d6c6